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Abstract
Background: IgE antibodies play a paramount role in the pathogenesis of various intestinal disorders. To gain insights in
IgE-mediated pathophysiology of the gut, we investigated the expression of the high affinity IgE receptor FceRI in human
intestinal epithelium.
Methodology/Principal Findings: FceRI a-chain, as detected by immunohistochemistry, was positive in epithelial cells for
eight of eleven (8/11) specimens from colon cancer patients and 5/11 patients with inflammation of the enteric mucosa. The
FceRIa positive epithelial cells co-expressed FceRIc, whereas with one exception, none of the samples was positive for the b-
chain in the epithelial layer. The functionality of FceRI was confirmed in situ by human IgE binding. In experiments with
human intestinal tumor cell lines, subconfluent Caco-2/TC7 and HCT-8 cells were found to express the a- and c-chains of
FceRI and to bind IgE, whereas confluent cells were negative for c-chains.
Conclusions/Significance: Our data provide the first evidence that the components of a functional FceRI are in vitro
expressed by the human intestinal epithelial cells depending on differentiation and, more importantly, in situ in epithelia of
patients with colon cancer or gastrointestinal inflammations. Thus, a contribution of FceRI either to immunosurveillance or
pathophysiology of the intestinal epithelium is suggested.
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Introduction
Although immunoglobulins are important constituents of host
defense in mucosal compartments [1], they have been ascribed
opposing functions in various intestinal diseases. Increased levels of
immunoglobulin E (IgE) have been found during parasite infection
with a putative beneficial host defense function [2,3]. In contrast,
IgE plays a documented detrimental role in allergy. Significantly
increased levels of IgE and anti-IgE autoantibodies might
contribute also to the pathophysiology in Crohn’s disease (CD)
[4]. Interestingly, it has been suggested that food allergic reactions
might be triggered as a consequence of gastrointestinal inflam-
mation [5,6]. Additionally, growing evidence points towards a
participation of IgE in antibody-dependent tumoricidal activities
[7–9].
IgE function depends on its interaction with effector cells via
specific surface-receptors. The high affinity IgE receptor (FceRI) is
a multimeric cell-surface receptor, which binds the Fc domain of
IgE with an affinity of 10
10 M
21 [10]. The conformational change
of the IgE constant region that occurs upon binding to FceRI was
proposed to contribute to the remarkably slow dissociation rate of
receptor-bound IgE [11]. FceRI has been so far detected on
human mast cells, basophils, neutrophils, monocytes, macrophag-
es, dendritic cells, Langerhans cells, eosinophils and platelets [12].
While the extracellular domain of the receptor a-chain carries the
IgE binding site [13], the b- and c-chains are involved in signal
transduction [14,15]. The abc2 tetramer is expressed in effector
cells such as mast cells and basophils, and ligand-engagement leads
to cell activation by a defined signaling cascade. In contrast, the
ac2 trimer participates in antigen presentation [16].
The low affinity IgE receptor (FceRII/CD23) is a single chain
glycoprotein with a molecular weight of 49 kDa [17]. In contrast
to FceRI, CD23 binds IgE with a significantly lower affinity
(10
7 M
21). CD23 was initially identified on B-lymphocytes [18]
but subsequently also detected on various other cell types such as
monocytes, macrophages, eosinophils and Langerhans cells
[17,19,20]. Interestingly, CD23 is also expressed on intestinal
epithelial cells where it is elevated in inflammatory conditions such
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transepithelial shuttle mechanism, regulated by interleukin (IL)-
4, has been described, which mediates transport of intact food
antigens [22–24].
Besides FceRI and FceRII/CD23, the IgE-binding protein
(eBP, Galectin-3) also specifically interacts with IgE [25]. Due to
its wide tissue distribution and expression on various cell types
[26], a multifunctional role in cell growth regulation, cell adhesion
and tumor metastases, among others, was suggested [27–29]. The
intestinal distribution pattern of eBP is well established and it has
been shown that it is downregulated in inflammation, whereas an
elevated expression in colon cancer influences the neoplastic
progression [30,31].
The presence of CD23 and eBP on intestinal epithelia is well
documented, and functional studies have supported their biolog-
ical importance. However, since no data were available concern-
ing expression of FceRI on enterocytes to date, we screened the
intestinal mucosa of patients with gastrointestinal pathologies and
controls, as well as intestinal epithelial cell lines for FceRI
expression. Herein, we report that both FceRI a- and c-chains are
expressed by intestinal epithelial cells, while FceRI b-chain could
only be detected in the subepithelial stroma. The IgE binding
found in a- and c-chain positive tissues indicates the presence of a
functional trimeric receptor FceRIac2 in human intestine, which
could contribute to IgE-mediated pathophysiology of the gut.
Results
The High Affinity IgE Receptor FceRI a- and c-Chains Are
Expressed on the Epithelium of Human Intestinal Tissue
Immunohistochemical (IHC) analysis revealed positive stain-
ing for FceRI a-chain in the intestinal epithelium in eight of
eleven (8/11) (73%) colon cancer patients and in 5/11 (45%)
patients with gastrointestinal inflammation. In most cases, both
small intestine and colon were positive for FceRI a-chain.
However, one patient per group (No. 24 and 12, respectively)
was positive only in the colon, and two tumor patients (No. 21
and 26) expressed FceRI a-chain only in the small intestinal
epithelium. The four control samples from patients without
gastrointestinal disorders were negative for FceRI a-chain,
suggesting that receptor expression might be observed only with
gastrointestinal pathology (Table 1). Figure 1 shows IHC analysis
of tissue sections from a representative colon cancer (A–F) and a
gastrointestinal inflammation patient (G–L). In the specimen
from the tumor patient (No. 16), the FceRI a-chain was
expressed in membrane and cytoplasm of the small intestinal
epithelial cells throughout the entire intestinal villus and crypt. At
the basal side of crypt cells, the positive staining was found also in
the supranuclear region, most likely the Golgi apparatus
(Figure 1A). Staining serial sections with the Paneth cell marker
defensin-5 identified FceRI a-chain positive cells in the small
intestinal crypts as Paneth cells (Figure 1D). The observed
staining in the patient with colon cancer was comparable to that
seen in the small intestine of the CD patient (No. 8, Figure 1G, J).
Interestingly, we observed a positive correlation between FceRI
staining in the epithelial cells of the ileum and colon: the majority
of patients expressing the receptor in the small intestine
(Figure 1A, G) had positive staining also in the colon
(Figure 1B, H). In addition, we found FceRI a-chain positive
cells in the tumor samples of colon cancer patients (6/11) and in
the lesion areas of three patients with gastrointestinal inflamma-
tions (3/11) (Table 1; Figure 1C, I).
Surface membrane localization of FceRI a-chain on small
intestinal epithelial cells was observed in tissue samples from 4/11
of cancer patients and in 4/11 of patients with gastrointestinal
inflammations (one small intestine, two small intestine + colon, one
colon). The IHC analysis as indicated in Table 1 was validated by
immunofluorescence (IF) staining.
We further confirmed that FceRI a-chain is expressed in small
intestinal, colonic and lesion/tumor epithelial cells by IF
double-staining with the epithelial cell marker cytokeratin 8
(Figure 2).
In addition to the a-chain subunit, a functional FceRI complex
requires the presence of a c-chain subunit, with or without a b-
subunit. Therefore, we conducted IF analysis to determine
whether the FceRIa-chain was co-expressed with either the b-
or c-chains. These experiments revealed a double-staining for a-
and c-chain along or at the top of the villi in all seven FceRIa
positive small intestinal tissue samples from tumor patients, as well
as in 3/4 FceRIa positive small intestinal tissue samples from
patients with gastrointestinal inflammation (Table 2; Figure 3A,
D). In addition to the small intestine, co-expression of the a- and c-
chain was observed in 4/6 FceRIa positive colon samples from
tumor patients and in 2/3 colon sections from gastrointestinal
inflammation patients (Table 2; Figure 3B, E). A correlation of c-
chain with a-chain co-expression was found in 4/6 FceRIa
positive tumor samples as well as in all lesional tissues (Table 2;
Figure 3C, F). Nevertheless, no positive staining for the FceRI c-
chain was observed in Paneth cells at the base of the crypts (data
not shown). In contrast to a- and c-chain co-expression, the b-
chain of FceRI could be detected, with one exception, only in cells
of the subepithelial stroma, but not in the intestinal epithelial layer
(Table 2; Figure 3G). The exception was colonic epithelial cells in
tumor patient No. 25 (Table 2), where FceRI b-chain was detected
exclusively in the supranuclear region, most likely the Golgi
apparatus.
Analysis of various clinical parameters, including patients’ age,
sex and pathological disease classification showed no association
with staining results for FceRI expression.
Epithelial FceRI Exhibits IgE Binding Properties
To determine whether the FceRIac2 expressed in the intestinal
epithelium had specific antibody binding capacity, we performed
IgE binding experiments on paraffin-embedded intestinal tissue
sections. Samples positive for FceRIa on the apical cellular
membrane (Figure 4A) showed specific binding of human serum
IgE or humanized anti-4-hydroxy-3-nitrophenylacetyl (NiP)-spe-
cific IgE (Figure 4B), with indistinguishable binding patterns. No
epithelial binding was seen with unspecific human IgG antibodies
or FITC-labeled dextran used as controls (data not shown). The
observed IgE-FceRI interactions correlated with the FceRI a-
chain expression in the epithelium, being expressed on the
epithelial membrane as well as in the cytoplasm (Figure 4A, B).
The IgE binding was not inhibited by anti-CD23 preincubation or
by lactose, indicating protein- rather than carbohydrate-mediated
IgE binding.
High Levels of FceRI a- and c-Chain mRNA Expression Are
Detected in Intestinal Epithelial Cell Lines
To analyze the expression of the FceRI complex on the
transcriptional level in human intestinal epithelial cells, total
RNA was isolated from subconfluent and confluent Caco-2/TC7
and HCT-8 cell lines. Human HMC-1 mast cells and transfected
RBL-SX38 cells were used as positive controls, because they are
known to abundantly express FceRI a-, b-a n dc-chains. Real-
time PCR analysis revealed the presence of the FceRI a-chain
mRNA in all four intestinal cell lines, with highest expression in
confluent HCT-8 cells (Figure 5A). The expression level was
FceRI on Intestinal Epithelium
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cells (data not shown). The c-chain mRNA also was found in all
four intestinal cell samples, with highest levels detected in
confluent Caco-2/TC7 cells (Figure 5B). In this case, the mRNA
expression level of c-chain was 80-times higher in the HMC-1
cells (data not shown). None of these intestinal epithelial cell lines
expressed detectable FceRI b-chain mRNA (data not shown). In
the second positive control cell line, high mRNA levels of all three
FceRI chains were observed, reflecting that these transfected
RBL-SX38 cells over-express FceRI (data not shown). Together,
these findings verify the presence of FceRI a-a n dc-chain
mRNA, the components of the trimeric FceRIac2 complex, in
human intestinal epithelial cells.
Highest Expression of FceRI a- and c-Chains Is Observed
in Undifferentiated, Subconfluent Intestinal Cell Lines
To screen intestinal epithelial cell lines for FceRI a-, b- and c-
chain protein expression we performed IF staining. We observed
abundant a-chain expression in undifferentiated, subconfluent
Caco-2/TC7 (Figure 6A, B) and HCT-8 cells (Figure 6E, F). To
exclude intracellular staining signals for FceRIa, we confirmed
membrane integrity by comparing Triton-X-100 permeabilized
cells with untreated controls using lamin A/C staining (Figure 6I,
J). The total (Figure 6A) and surface-membrane expression
(Figure 6B) were comparable in Caco-2/TC7 cells, whereas in
subconfluent HCT-8, the surface expression of FceRIa was less
pronounced (Figure 6F) compared to the staining observed in the
Table 1. Patients’ characteristics and staining results.
Small intestine Colon Lesion/tumor
Pat. No. Sex Age Pathology (Tumor staging) FceRI-a Def. 5 FceRI-a Def. 5 FceRI-a Def. 5
1 f 41 –(obese patient) 2 + n.d. n.d. n.a. n.a.
2 f 39 –(obese patient) 2 + n.d. n.d. n.a. n.a.
3 f 19 –(biopsy, diarrhea, meteorism) 2 + 22 n.a. n.a.
4f 5 0 – 2 + n.d. n.d. n.a. n.a.
5 m 47 Crohn’s disease, active phase + Pc, M, sV ++ +++
6 f 35 Crohn’s disease, active phase 2 + 22 2 +
7 f 27 Crohn’s disease, active phase 2 + 2 + 2 +
8 f 37 Crohn’s disease, active phase + Pc, M, V ++ M +++
9 m 19 Crohn’s disease, active phase 2 + 22 2 +
10 f 61 Crohn’s disease, active phase 2 + 22 2 +
11 m 28 Crohn’s disease, active phase 2 + 22 2 +
12 f 29 Crohn’s disease, active phase 2 ++ M 22+
13 m 50 Diverticulitis and Peridiverticulitis 2 + 22 2 +
14 f 82 Inflammation + Pc, M, V ++ M +++
15 f 30 C-Gastritis (biopsy) + Pc + n.a. n.a. n.a. n.a.
16 m 66 Invasive, moderately well differentiated adenocarcinoma,
ascending colon (G2, pT3, pN2, pM1, Dukes D)
+ Pc M, V ++ +++
17 f 78 Invasive, moderately well differentiated adenocarcinoma,
ascending colon (G2, pT2, pN1, Dukes C1)
2 + 2 222
18 f 69 Invasive, moderately well/moderately differentiated
adenocarcinoma, Cecum (G2/G3, pT3, pN1, Dukes C)
22 2 2 2 +
19 f 67 Invasive, low differentiated adenocarcinoma, ascending
c o l o n( G 3 ,p T 3 ,p N 0 ,p M 1 )
+ Pc ++ 2 + 2
20 m 76 Invasive, low differentiated adenocarcinoma, ascending
colon (G3, pT3, pN0, pMX, V1)
+ Pc, M, V ++ 222
21 m 84 Invasive, well differentiated adenocarcinoma, ascending
colon (G1, pT2, pN0, pMX, Dukes B)
+ Pc, sV + 2 ++2
22 m 70 Invasive, moderately well/moderately differentiated
adenocarcinoma, ascending colon (G3, pT3, pN2, pMX,
Dukes C1)
2 + 2 222
23 m 68 Invasive, moderately well differentiated adenocarcinoma,
Cecum (G2, pT3, pN0, pMX, Dukes B)
+ Pc, M 2 + 2 + 2
24 m 57 Invasive, moderately well differentiated adenocarcinoma,
Cecum (G2, pT4, pN0, V1, Dukes B)
2 ++ +22
25 m 79 Invasive, moderately well differentiated adenocarcinoma,
ascending colon (pT3, pN0, pMX, Dukes B)
+ Pc, M ++ 2 + 2
26 f 86 Invasive, moderately well differentiated adenocarcinoma,
ascending colon (pT4, pN2, pM1, V1, L1, Dukes D)
+ Pc, V ++ +++
n.d., not determined; n.a., not applicable; Pc, Paneth cell staining; M, Membrane staining; sV, single cell staining in villi; V, all villus epithelium.
doi:10.1371/journal.pone.0009023.t001
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with confluency, as only a faint staining could be detected in the
cytoplasma of confluent Caco-2/TC7 (Figure 6C) and HCT-8
cells (Figure 6G). No FceRIa positive staining was observed on the
membrane of confluent Caco-2/TC7 cells (Figure 6D). In the
HCT-8 cells grown as multilayers with the new cells revealing a
more immature phenotype, a scarce positivity was seen
(Figure 6H).
We could not detect FceRIb in any intestinal epithelial cell line
irrespective of the state of confluence (Figure 7A, D, G, J). In
Figure 1. Positive staining for FceRI a-chain and defensin-5 is observed in serial sections from intestinal tissue. (A) FceRI a-chain is
detected on the membrane, as well as in the cytoplasm of epithelial cells in small intestine of cancer patient No. 16. FceRI a-chain positive cells are
also found in (B) the colon and (C) a tumor sample from the same patient. (D) Staining with anti-defensin-5 antibodies confirmed that FceRIa
expressing cells at the basis of the small intestinal crypts are Paneth cells. Defensin-5 is expressed also in (E) colon and (F) tumor sample in same
areas, but to a lesser extend when compared with FceRI a-chain staining. Similar staining pattern are observed also for the CD patient No. 8, as FceRI
a-chain positive cells are detected in (G) the epithelium of small intestinal tissue, (H) colon and (I) lesional region. Defensin-5 positive cells are located
at (J) the crypt basis of small intestine, (K) along the colon crypt, as well as in (L) the lesional region. Original magnification 610, inset 640.
doi:10.1371/journal.pone.0009023.g001
Figure 2. FceRI a-chain is expressed in epithelial cells. Co-staining with anti- FceRI a-chain (red) and anti-keratin 8 antibodies (green) verifies
the epithelial expression of FceRI in (A) the crypts of small intestinal section, where FceRIa is found primarily in the supranuclear region, in (B) colon
tissue and in (C) tumor sample of cancer patient No. 16. (D) Negative control with mouse IgG2b and rabbit IgG. The blue fluorescence DAPI staining
indicates the nuclei. Original magnification 640.
doi:10.1371/journal.pone.0009023.g002
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subconfluent Caco-2/TC7 (Figure 7B) and HCT-8 cells
(Figure 7H), but not after confluence (Figure 7E, K). Consistent
with these results, binding of IgE was high in the subconfluent
Caco-2/TC7 (Figure 7C) and HCT-8 cells (Figure 7I), whereas
only a background staining was seen in confluent Caco-2/TC7
(Figure 7F) and HCT-8 (Figure 7L) cells. The IgE binding was not
inhibited by anti-CD23 preincubation.
The IF staining of Caco-2/TC7 and HCT-8 cells was
confirmed by western blot analysis with cell lysates obtained from
subconfluent and confluent cells. We observed a 45-kDa protein
band of FceRI a-chain in all cell lysates, with a stronger signal in
Table 2. FceRI b- and c-chain staining results in FceRI a-chain expressing intestinal tissue.
Small intestine Colon Lesion/tumor
Pat. No. FceRI-a FceRI-b FceRI-c FceRI-a FceRI-b FceRI-c FceRI-a FceRI-b FceRI-c
5 + 2 ++2 ++2 +
8 + 2 ++2 ++2 +
14 + 2 ++22+ 2 +
15 + 22n.a. n.a. n.a. n.a. n.a. n.a.
16 + 2 ++2 ++2 +
19 + 2 ++22+ 22
20 + 2 ++22222
21 + 2 + 222+ 22
23 + 2 ++2 ++2 +
25 + 2 +++++2 +
26 + 2 ++2 ++2 +
n.a., not applicable;
doi:10.1371/journal.pone.0009023.t002
Figure 3. Co-expression of FceRI a- and c-chain, but not FceRI a- and b-chain is observed in epithelial cells of intestinal tissue. In
sections from cancer patient No. 23 FceRI c-chain (green) is found to be co-expressed in FceRIa (red) positive epithelial cells of (A) the small intestine,
as well as in (B) colon tissue and (C) tumor sample. In addition, sections from CD patient No. 8 are double-positive for FceRI a- and c-chain in (D) the
small intestinal, (E) colon and in (F) lesional tissue. (G) Only in the subepithelial tissue FceRI b-chain (green) positive cells are detected as shown here
in the crypts of small intestinal tissue. (H) Negative control with mouse IgG2b and goat IgG isotype control antibodies. The blue fluorescence DAPI
staining indicates the nuclei. Original magnification 664.
doi:10.1371/journal.pone.0009023.g003
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even though FceRI a-chain is known to be glycosylated. In
contrast, we could detect the 10 kDa protein band of FceRI c-
chain only in subconfluent Caco-2/TC7 and HCT-8 cells
(Figure 8B). Both the a- and c-chains were detected in the
positive control RBL cell line over-expressing the human FceRI
(Figure 8B). High amounts of expressed FceRI a- and c-chain
proteins were seen in the human mast cell line HMC-1 (data not
shown). Thus, our data indicate that a functional high affinity IgE
receptor is expressed by these cell lines when they are subconfluent
and not after confluence.
Discussion
In the present study, we investigated the expression of FceRI in
the human intestinal epithelium and analyzed the role of cell
growth or confluency on receptor expression in intestinal epithelial
cell lines. We observed pronounced FceRI a-chain expression in
73% of colon cancer patients and in 45% with gastrointestinal
inflammations. In vitro experiments revealed only undifferentiated,
subconfluent intestinal epithelial cells to express the a- and c-
chains of FceRI. The functionality of the receptor was evident by
the specific binding of IgE to the FceRI a-chain.
It is easy to speculate that IgE antibodies might contribute to
gastrointestinal inflammatory disorders [4–6]. The expression of
the IgE high affinity receptor in cancer patients could have
beneficial or detrimental effects. On the one hand, IgE antibodies
have been suggested to participate in tumor immunosurveillance
[9]. However, other facts could argue for a role of FceRI in
tumorigenesis. IgE binding to FceRI was previously reported to
both stabilize the receptors on the surface leading to receptor
accumulation [32], but also to enhance survival of FceRI bearing
mast cells by autocrine cytokine secretion and induction of an anti-
apoptotic protein [33]. Additionally, FceRI signaling induces Ras
activity, which in mast cells is associated with cell growth,
differentiation and survival. Similarly, Ras initiates neoplastic cells
proliferation via the inositol (1,4,5) triphosphate 3-kinase and ERK
signaling [34,35]. Therefore, our data on FceRI expression in
colon tumor specimens, as well as in subconfluent, proliferating
cell lines, might reflect a role for this receptor in tumor cell growth
and survival.
It is well known that intestinal epithelial cells express HLA class
II antigens on their surface and therefore are able to function as
antigen presenting cells [36,37]. Interestingly, the cross-linking of
trimeric FceRIac2 expressed on professional antigen presenting
cells [12] by IgE and bound antigen was shown to induce
endocytosis of the complex and uptake into MHC class II-rich
compartments [16]. In this context, in IgE mediated disorders
such as allergy a more enhanced efficiency of antigen-presentation
to T cells was reported [38,39]. Thus, expression of FceRI might
contribute to the antigen presenting function of intestinal epithelial
cells.
It is also possible that intestinal epithelial expression of FceRI
could exert a shuttle function for specific IgE through the intestinal
epithelium. In diseases with elevated levels of IgE antibodies an
increased intestinal transepithelial transport of IgE antibodies has
been demonstrated, resulting in detectable amounts of IgE
antibodies in feces [40]. From animal experiments, it is known
that this IgE transport to the lumen occurs through intact
Figure 4. FceRI positive tissue reveals IgE binding activity. Immunofluorescence staining of serial sections from patient No. 8 revealed IgE
binding in (A) FceRI a-chain (red) positive epithelial cells being incubated with (B) monoclonal NiP-specific humanized IgE antibodies (green). (C)
Negative control with PBS. The blue fluorescence DAPI staining indicates the nuclei. Original magnification 640.
doi:10.1371/journal.pone.0009023.g004
Figure 5. Expression of FceRI a- and c-chain but not b-chain
mRNA in human intestinal epithelial cells. The expression pattern
of the FceRI complex was analyzed by real-time PCR analysis using
specific primers for detection of (A) FceRI a-, b- (not shown), and (B) c-
chain. Target gene expression levels were normalized to the average of
housekeeping genes and are depicted relative to the value of
subconfluent Caco-2/TC7 cells. The values are presented as means +/2
SD (n=3) from one experiment. The results are representative of two
independent experiments.
doi:10.1371/journal.pone.0009023.g005
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regarding the mechanisms of this transepithelial IgE transport,
even though antibody-binding structures seem to play a defined
role. So far, only CD23 has been implicated in enhanced IL-4
dependent antibody shuttling through the intestinal epithelium
[22,23]. The same IgE/CD23 shuttle mechanism seems to be
responsible for transepithelial food allergen uptake and protect the
antigens from degradation during this transport [24]. Based on the
data presented here, FceRI on enterocytes could contribute to IgE
transfer through the gut epithelium. As no inhibition of IgE
binding was seen in our experiments using anti-CD23 antibodies,
the higher affinity of FceRI to the Fc domain of IgE [10] could
possibly enhance IgE transport.
Upon screening of the intestinal epithelium for FceRI we found
FceRI a- but not c-chain expression at the base of the crypts at the
level of Paneth cells, as suggested by previous work of our group
[42]. Interestingly, intracellular expression and cellular release of
FceRIa was reported for other cell types such as eosinophils [43]
and soluble IgE receptors were found to exert distinct biological
functions such as regulation of IgE production, T cell and
granulocyte maturation and macrophage migration [44]. Thus,
Paneth cells might be of special interest as they contribute
substantially to innate immunity in the intestine [45]. Further,
Paneth cells appear to have a central role in some forms of
inflammatory bowel disease [46]. Paneth cells are primarily present
in small intestinal tissue in healthy individuals. However, metaplas-
tic defensin-5 positive cells were found in the upper gastrointestinal
tract and the diseased colon, and are considered an early marker of
epithelial dysplasia and cancer development [47,48]. In contrast to
the absorptive epithelial cells, which migrate from the crypts to the
top of the villi during their 4–6 days lifespan [49], Paneth cells are
found adjacent to the rapidly dividing pluripotent stem cells. Thus,
alternative maturation signals are crucial for Paneth cell differen-
tiation [50]. Even though real-time PCR analysis revealed the
presenceoftheFceRIa- andc-chainsmRNAinconfluentintestinal
cells, only undifferentiated proliferating cells expressed a functional
FceRIac2 as detected by cellular IF staining and Western blot
experiments. This expression was decreased in confluent, differen-
tiated cells. Thus, protein expression of FceRI a- and c-chain in
intestinal epithelial cells might be mainly regulated on the
translational level.
Our data demonstrate that the FceRI a- and c-chains, which
are crucial components of the heterotrimeric FceRIac2 isotype,
are expressed in intestinal epithelial cells of patients with colon
cancer or gastrointestinal inflammation. Although these data do
not elucidate the precise function of FceRI in the intestinal
epithelium, the novel findings suggest that FceRI may contribute
to immunosurveillance or pathophysiology at the intestinal
mucosa.
Materials and Methods
Patient Samples
Four-micron sections of formalin fixed (buffered formalin,
pH 7.5) paraffin-embedded tissue of small intestinal and colon
specimens were investigated. The samples were obtained from
eleven patients with gastrointestinal inflammations and eleven
patients with colon cancer. In each case, mucosa with pathological
changes as well as regular mucosa without any histological signs of
abnormality was investigated. Additionally, sections of biopsies
Figure 6. Abundant surface and cytoplasmatic FceRI a-chain expression only in subconfluent human intestinal tumor cell lines.
Immunofluoresence staining for (A–H) FceRIa is performed in (A, B) subconfluent and (C, D) confluent Caco2/TC7 as well as in (E, F) subconfluent and
(G, H) confluent HCT-8. Triton-X-100 permeabilized (A, C, E, G) and untreated cells (B, D, F, H) were compared. (I–L) Representative control staining in
subconfluent Caco2/TC7 with the (I, J) anti-lamin A/C or (K, L) unspecific murine IgG2b, (I, K) permeabilized or (J, L) untreated. The blue fluorescence
DAPI staining indicates the nuclei. Original magnification 640.
doi:10.1371/journal.pone.0009023.g006
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control purposes. Patient characteristics are summarized in
Table 1. The inclusion of human specimens for the present study
was approved by the ethic’s committee of the Medical University
Vienna (number: 317/2007). The protocol permitted only usage of
numerically coded human tissue sections from therapeutical
interventions. The authors of the study had no access to patients’
data except the information given in Table 1. Thus, the ethic’s
committee of the Medical University Vienna waived informed
consent.
Antibodies
We used the following anti-human primary antibodies in this
study: mouse monoclonal anti-FceRI a-chain (clone CRA1)
purchased from Cosmo Bio (Co., Tokyo, Japan), rabbit polyclonal
anti-FceRI a-chain purchased from Upstate (Lake Placid, NY),
mouse monoclonal anti-defensin-5 (clone 1G11) generated by C.
L. Bevins [47], goat polyclonal anti-FceRI b-chain, goat
polyclonal anti-FceRI c-chain, mouse monoclonal anti-CD23
(clone BU38) and goat polyclonal anti-lamin A/C purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz CA), rabbit
polyclonal anti-FceRI c-chain purchased from Abcam (Cam-
bridge, UK), rabbit anti-keratin 8 purchased from NeoMarkers
Inc (Fremont, CA), mouse monoclonal anti-actin purchased from
Chemicon International, (Millipore, Billerica, MA); human serum
IgE purchased from Alpha Diagnostic Intl. Inc. (San Antonio
TX), humanized murine anti-NiP IgE antibody purchased from
Serotec (Oxford, UK). Non-specific mouse IgG1 and IgG2b
(Jackson ImmunoResearch Laboratories, West Grove, PA), non-
specific goat IgG (Zymed Laboratories San Francisco, CA) and
non-specific rabbit IgG (Serotec, Oxford, England) served as
negative controls. Specific binding of antibodies was detected
using the following secondary antibodies or detection reagents:
goat anti-mouse AlexaFluor 568-conjugated and goat anti-rabbit
AlexaFluor 488-conjugated purchased from Molecular Probes
(Invitrogen, Carlsbad, CA), biotinylated rabbit anti-goat and
FITC-Streptavidin purchased from Dako (Carpinteria, CA),
FITC-labeled donkey anti-goat (Jackson ImmunoResearch Lab-
oratories), FITC-labeled goat anti-human IgE purchased from
Vector Laboratories (Burlingame, CA); HRP-conjugated anti-
rabbit purchased from Amersham Biosciences (GE Healthcare,
UK), HRP-conjugated anti-mouse purchased from Jackson
Immunoresearch Laboratories. 4-hydroxy-3-nitrophenylacetyl
Figure 7. Abundant FceRI c-chain expression and IgE binding in subconfluent human intestinal tumor cell lines. Immunofluorescence
staining of (A, D, G, J) FceRI b- and (B, E, H, K) FceRI c-chain are performed in (A–C) subconfluent and (D–F) confluent Caco2/TC7 and in (G–I)
subconfluent and (J–L) confluent HCT-8. (C, F, I, L) According to the expression pattern of FceRI in the subconfluent cells, IgE binding is observed
exclusively in subconfluent, non-mature intestinal cells. The blue fluorescence DAPI staining indicates the nuclei. Original magnification 640.
doi:10.1371/journal.pone.0009023.g007
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purchased from Biosearch Technologies (Novato, CA). FITC
labeling of NiP-BSA was performed with the EZ-Label FITC
protein labeling kit (Pierce, Rockford, IL) following the manu-
facturer’s instructions.
Immunohistochemical Staining of Intestinal Tissue
Sections
The IHC staining procedure is described elsewhere [51].
Briefly, sections were deparaffinized and rehydrated. After antigen
retrieval with 10 mM citrate buffer pH 6, the endogenous
peroxidase activity was quenched by exposure to 3% H2O2 in
methanol. Sections were permeabilized with PBS/0.2% Tween,
and unspecific antibody binding was blocked with 5% horse
serum. The primary antibodies used were mouse monoclonal anti-
FceRI a-chain (Cosmo Bio), and mouse monoclonal anti-defensin-
5 (clone 1G11) [47]. Murine IgG1 and IgG2b served as negative
controls. After washing, the sections were further processed with a
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA)
following the manufacturer’s instructions. Color reaction was
developed with a DAB
+ chromogen kit (Dako). After counter-
staining with hematoxylin the sections were dehydrated and
mounted with Eukitt, and then analyzed using a Nikon Eclipse
E400 microscope (Nikon, Vienna, Austria).
Immunofluorescent Double-Staining
Sections were treated as described above with slight modifi-
cations. After antigen unmasking with 10 mM citrate buffer
pH 6 and permeabilization with PBS/0.2% Tween, the sections
were blocked with 5% goat serum. For the FceRI a-chain/
cytokeratin 8 double staining, the first primary antibody applied
was mouse anti-FceRI a-chain (Cosmo Bio) overnight at 4uC.
Mouse IgG2b served as negative control. After washing goat anti-
mouse AlexaFluor 568 was applied for 1 h. After washing and
blocking again with 5% goat serum, the second staining was
performed using rabbit anti-keratin 8 as the second primary
antibody (or rabbit IgG as negative control) for 1 h. After
washing, goat anti-rabbit AlexaFluor 488 secondary antibody
was applied for 1 h. For the double-staining of FceRI a-chain
with FceRI b-o rc-chain the first primary antibody applied was
goat anti-FceRI b-o rc-chain overnight at 4uCa f t e rb l o c k i n g
with 5% rabbit serum. Goat IgG was used as negative control.
After washing the sections were incubated with biotinylated
polyclonal rabbit anti-goat Ig for 30 min at 37uC. The sections
were again washed and incubated with FITC-Streptavidin for
30 min at room temperature. After washing and blocking again
with 5% goat serum, the second staining was performed using the
mouse anti-FceRI a-chain as the second primary antibody (or
mouse IgG2b as negative control) for 1 h. After washing goat
anti-mouse AlexaFluor 568 was applied for 1 h. The sections
were washed and counterstained with 49,6-Diamidino-2-pheny-
lindole 0.1 mg/ml (Molecular Probes). Afterwards, sections were
mounted in Vectashield medium (Vector Laboratories) and
investigated in a Zeiss Axioplan 2 microscope (Carl Zeiss
Go ¨ttingen, Germany).
Human IgE Binding in Intestinal Tissue Sections
For IgE binding experiments, human intestinal sections were
cleared in xylene, rehydrated and subjected to heat-mediated
antigen retrieval as described above. Residing antibodies were
stripped by low pH treatment, and unspecific binding sites were
blocked with 5% BSA/PBS for 30 min. To block IgE binding to
Galectin and CD23, a-Lactose 25 mM and anti-CD23 (clone
BU38) were applied overnight at 4uC. Thereafter, slides were
incubated with 10 mg/ml NiP-IgE, serum IgE or PBS for 2 h at
37uC. For controls, either 5 mg/ml FITC-labeled IgG or dextran
in PBS/1% BSA were incubated overnight at 4uC under light
protection. The sections were then incubated with either FITC-
labeled NiP-BSA (NiP-IgE) or goat anti-human IgE (NiP-IgE and
serum IgE). The sections were further processed for IF or IHC
analysis as described above. Only the results generated with NiP-
IgE/FITC-labeled anti-human IgE are shown.
Cell Culture
All cell culture media were supplemented with 10% heat
inactivated FCS (PAA Laboratories, Pasching, Austria), 4 mM
glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin if
not explicitly stated. The human adenocarcinoma cell line HCT-8
(originating from the ileocecal region) (kindly provided by Gerhard
Hamilton, Department of Surgery, Medical University Vienna,
Vienna, Austria) was grown in RPMI 1640 supplemented with
10% FCS (PAA Laboratories, Pasching, Austria) and 4 mM
glutamine. The human colon adenocarcinoma cell line Caco-2
clone TC7 (Caco-2/TC7) (kindly provided by Monique Rousset,
INSERM, Paris, France) was grown in Dulbecco modified
Figure 8. Western blot analysis reveals FceRI in human
intestinal tumor cell lines. (A) FceRI a-chain and (B) FceRI c-chain
expression is investigated in Caco2/TC7 and HCT8 subconfluent and
confluent cell lines. In all experiments RBL cells transfected with the
human FceRI receptor served as positive controls and the protein
expression signal was normalized to the expression of house-keeping
protein actin.
doi:10.1371/journal.pone.0009023.g008
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(4500 mg/ml), supplemented with 1% non-essential aminoacid,
10 mM HEPES. Cells were used at subconfluent stage (60%
confluence) or 10 days after confluency. For all experiments RBL-
SX38 cells which are transfected with the complete human FceRI
(kindly provided by Jean-Pierre Kinet, Harvard Institute of
Medicine, Boston, MA) and human HMC-1 mast cells (kindly
provided by Joseph H. Butterfield, Mayo Clinic, Rochester, MN)
served as a positive control. RBL-SX38 cells were cultured in
RPMI 1640 medium, HMC-1 cells were grown in IMDM.
RNA Isolation, Reverse Transcription and Real-Time PCR
Analysis
Total RNA was isolated from subconfluent and confluent
human Caco-2/TC7 and HCT-8 intestinal cell lines by using the
RNeasy RNA isolation Kit (Qiagen, Vienna, Austria), including
on-column DNase digest following the manufacturer’s instruction.
RNA integrity was analyzed by agarose gel electrophoresis. RNA
concentration and purity was determined using a Biophotometer
(Eppendorf, Hamburg, Germany). RNA isolated from HMC-1
and RBL-SX38 cells was used as a positive control for evaluation
of target gene (human FceRI a-, b-, and c-chain) expression. Two
mg of total RNA were transcribed into cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Vienna, Austria).
Expression analysis was performed by real-time PCR on a
StepOne Plus real-time PCR system (Applied Biosystems). The
analysis was carried out with a two step protocol starting with 20
seconds at 95uC, followed 40 cycles of 1 second at 95uC and
subsequent 20 seconds at 60uC. In all experiments triplicates were
set up containing the POWER SYBR Green PCR Master Mix
(Applied Biosystems) reagent. Primers were designed using
‘‘Primer Express 2.x’’ software (Applied Biosystems) and span,
when possible, exon–intron boundaries to avoid signals from
contaminating genomic DNA. The forward (fwd) and reverse (rev)
primers consist of the following sequences: beta Actin fwd:
tggctcccgaggagcac, rev: ccttaggtttctgagggactgcta; RPLP0 fwd:
cctcatatccgggggaatgtg, rev: gcagcagctggcaccttattg; FceRIa fwd:
catggaatcccctactctactgtgt, rev: ccttaggtttctgagggactgcta; FceRIb
fwd: gagaaatgcaacatatctggtgagag, rev: aggttgatgatcaggatggtaattc;
FceRIc fwd: caagtgcgaaaggcagctataa, rev: tgctcaggcccgtgtaaac.
Based on melting curve analysis no primer–dimers were
generated during the PCR amplification. For relative quantifica-
tion, data were analyzed by DDCT method using ‘‘StepOne
software 2.0’’ (Applied Biosystems). Expression levels of target
genes were normalized to the average of house keeping genes,
beta-actin and RPLP0, and are shown relative to the value of
subconfluent Caco-2/TC7.
Cell Immunostaining
Cells grown on glass cover slips were fixed for 20 min in 3%
paraformaldehyde. After washing, the cells were incubated for
15 min with 50 mM NH4Cl to reduce spontaneous fluorescence.
Unspecific binding sites were subsequently blocked by incubating
cells with 5% goat serum. Cells were treated with mouse
monoclonal anti-FceRI a-chain (clone CRA1), goat polyclonal
anti-FceRI b-chain or goat polyclonal anti-FceRI c-chain (Santa
Cruz Biotechnology Inc.) overnight at 4uC. Unspecific Mouse
IgG2b or goat IgG were used as negative control. After washing
the cells incubated with anti-FceRI a-chain were treated with goat
anti-mouse AlexaFluor 568 for 1 h. The cells incubated with anti-
FceRI b-chain or anti-FceRI c-chain were treated with biotiny-
lated polyclonal rabbit anti-goat Ig for 30 min at 37uC followed by
FITC-Streptavidin for 30 min at room temperature. For the
cellular IgE binding assay a blocking step with anti-CD23
antibodies (clone BU38) applied overnight at 4uC was followed
by incubation with 10 mg/ml NiP-IgE, serum IgE or PBS for 2 h
at 37uC. The cells were then incubated with either FITC labeled
NiP-BSA (NiP-IgE) or anti-human IgE antibodies (NiP-IgE and
serum IgE). The cells were further processed for immunofluores-
cence analysis as described above. Only the experiments
conducted with NiP-IgE/FITC labeled anti-human IgE are
shown.
To analyze for membranous or total expression of FceRI a-
chain, cells were either permeabilized with 0.2% Triton-X-100 for
30 min, or left with PBS. Goat anti-lamin A/C antibody was used
as positive control.
Cell lysate and Western Blotting Analysis
Total protein cell extract and western blot analysis was
performed as described before [52]. Briefly, after washing cells
were homogenized in 1 ml lysis buffer (10 mM TRIS pH 7.4
containing 1% SDS). The lysate was boiled for 5 min, centrifuged
at 1000 g, and then stored at 280uC. Equal amounts of protein
were separated by 12% SDS-PAGE and blotted to a nitrocellulose
membrane. Nonspecific binding sites were blocked with dried
milk powder in PBS/0.1% Tween. The antibodies used were
rabbit polyclonal anti-FceRI a-chain (Upstate), rabbit polyclonal
anti-FceRI c-subunit (Abcam), or mouse monoclonal anti-actin.
As secondary antibodies HRP-conjugated anti-rabbit antibody
(Amersham Biosciences) or HRP-conjugated anti-mouse antibody
(Jackson Immunoresearch Laboratories) were used. Bands were
detected with the SuperSignal CL-HRP Substrate system (Pierce,
Rockford, IL) and quantified by densitometry (EasyWin, Herolab,
Wiesloch, Germany).
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